Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive Article
3 Ways to Invest in the Growing GLP-1 Weight Loss MarketWritten by Nathan Reiff. Publication Date: 4/17/2026. 
Key Points
- The GLP-1 agonist market could triple in the coming years, and a number of new players are attempting to gain access to the space with novel drugs in development.
- Structure Therapeutics may warrant a closer look from investors, as its GLP-1 agonist candidate has shown promising trial results.
- It's also now possible to gain diversified exposure to the market via ETFs like OZEM and THNR, the former of which in particular has performed well in the last year.
- Special Report: Elon Musk already made me a “wealthy man”
Weight-loss drugs are big business. The GLP-1 receptor agonist market is projected to nearly triple to $185 billion by 2033, implying a compound annual growth rate of about 12.4%. While the trend is global, the United States still accounts for the lion's share of the market, and U.S. investors can gain exposure by targeting companies that manufacture these drugs. It's a mistake to assume that sales will be limited to major products like Ozempic or Wegovy, both from pharma giant Novo Nordisk A/S (NYSE: NVO). Demand is so strong that a growing number of alternatives are emerging despite the dominance of a few large players. Below, we profile a lesser-known biotech developer with a promising candidate and two exchange-traded funds (ETFs) that offer broader, diversified exposure to the industry. A Pivot Toward GLP-1 Drugs Could Be Transformational for Structure Therapeutics
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
Structure Therapeutics (NASDAQ: GPCR) is a biotechnology company focused on drugs that target G protein-coupled receptors (GPCRs). Historically it has pursued treatments for metabolic and inflammatory diseases such as fibrosis and nonalcoholic steatohepatitis. More recently, the company has pivoted toward GLP-1 therapeutics. Its candidate, aleniglipron, has shown roughly 16.3% weight loss after adjustments for certain trial factors, and may offer advantages over some rivals on safety and manufacturing cost. Structure is not yet profitable, but it holds a solid cash position of about $1.4 billion. That balance should provide runway over the coming quarters as aleniglipron advances toward a pivotal Phase 3 trial. Analysts have taken notice: 15 of 18 ratings on GPCR are Buy or equivalent. The shares have dipped roughly 20% year to date amid challenging external conditions, but with a consensus price target near $110, the stock could potentially more than double from current levels. The First GLP-1 Agonist ETF Is Building a Track Record of SuccessThe proliferation of GLP-1-focused ETFs reflects the sector's potential. An early entrant was the Roundhill GLP-1 & Weight Loss ETF (NASDAQ: OZEM), which launched in mid-2024. The actively managed fund takes a relatively concentrated approach, targeting about two dozen pharmaceutical and related companies positioned to benefit from growth in the GLP-1 space. Novo Nordisk and rival Eli Lilly & Co. (NYSE: LLY) together account for nearly 30% of the portfolio. The fund also includes a mix of domestic and international names to provide geographic diversification. OZEM offers exposure not just to companies producing GLP-1 therapies, but also to firms developing complementary weight-loss technologies and to suppliers supporting the production supply chain. As an actively managed ETF, OZEM carries an expense ratio of 0.59%—higher than many passive ETFs but competitive among active strategies. Its niche focus means a modest asset base (about $52 million) and relatively low trading volumes. Still, OZEM has returned an impressive ~45% over the past year, benefiting buy-and-hold investors. A modest dividend is an additional perk. Another GLP-1 ETF With a Passive ApproachA passive alternative is the Amplify Weight Loss Drug & Treatment ETF (NYSEARCA: THNR). Like OZEM, THNR charges an annual fee of 0.59% and holds roughly two dozen pharmaceutical names tied to the GLP-1 market. Novo Nordisk and Eli Lilly are also heavily represented, though together they make up about a quarter of THNR's portfolio, leaving more room for other companies. The key difference is that THNR is index-based rather than actively managed. Its weightings are determined primarily by float-adjusted market capitalization (and influenced by trading volume), and the portfolio is rebalanced quarterly. Some investors prefer this passive, market-reflective approach to active management. On the flip side, THNR's asset base is very small—around $4 million—with low trading volume. The fund has returned roughly 30% over the past year, which is in line with broader market gains but behind OZEM's performance. |
Post a Comment
Post a Comment